Evidence-Based Principles for Bipolar Disorder Treatment
FOCUS, APA's clinical review and continuing medical education journal, is designed as a personal study resource to help practicing psychiatrists keep abreast of significant advances in the field, with particular attention to clinical practice and incorporation of core competencies. The goal of FOCUS is the dissemination of up-to-date clinical information, facilitation of lifelong learning skills, maintenance of certification, and opportunity for self-assessment in order to improve patient care. Each issue, prepared by distinguished faculty who are recognized in their fields, provides up to date clinical information and incorporates a CME component. The material can be used effectively by establishing a regular schedule of study.
Program Planners – Editor and Associate Editors and Guest Editors
Mark H. Rapaport, MD, Editor of FOCUS, and Chairman and Chief of Psychiatric Services, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga. No financial relationships with commercial interests.
Dorothy Stubbe, MD, Editor and Author, Communications Commentary, Associate Professor and Program Director, Yale University School of Medicine Child Study Center, New Haven, CT.- No financial relationships with commercial interests.
Laura Dunn, MD, Co-Editor Ethics Column; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA; Dr. Dunn reports: Consultant: Otsuka America Pharmaceutical Inc.
Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes
Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better
Joseph F. Goldberg, M.D. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City.
Dr. Goldberg is a consultant for Lundbeck, Neurocrine, Otsuka, Sunovion, and WebMD. He is on the speakers bureaus for Allergan, Neurocrine, Otsuka, Sunovion, and Takeda-Lundbeck. Dr. Goldberg receives royalties from American Psychiatric Association Publishing.
Psychopharmacology and Experimental Therapeutics for Bipolar Depression
Manish K. Jha, M.B.B.S., and James W. Murrough, M.D., Ph.D. Depression and Anxiety Center for Discovery and Treatment and Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York City. Dr. Jha has received contract research grants from Janssen Research and Acadia Pharmaceuticals. Dr. Murrough has provided consultation services to Clexio Biosciences, Boehreinger Ingelheim, Sage Therapeutics,FSV7, Novartis, Allergan, Fortress Biotech, Janssen Research and Development, Medavante-Prophase, and Global Medical Education and has received research support from Avanir Pharmaceuticals, Inc. Dr. Murrough is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders. The Icahn School of Medicine (employer of Drs. Jha and Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine if it is approved for the treatment of depression. Drs. Jha and Murrough are not named on this patent and will not receive any payments.
Evidence-Based Psychotherapies for Bipolar Disorder
Danielle M. Novick, Ph.D., and Holly A. Swartz, M.D. Outpatient Mood Disorders Clinic and Clinical Training Committee, VA Pittsburgh Healthcare System, Pittsburgh (Novick); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Swartz). Dr. Novick reports no financial relationships with commercial interests. Dr. Swartz has received consulting fees from Otsuka and Myriad Genetics, grant support from Myriad Genetics, royalties from UpToDate, and an editorial stipend from American Psychiatric Association Publishing for her role as editor of the American Journal of Psychotherapy.
Psychopharmacological Decision Making in Bipolar Disorder During Pregnancy and Lactation: A Case-by-Case Approach to Using Current Evidence
Elizabeth Albertini, M.D., Carrie L. Ernst, M.D., Rachel S. Tamaroff, M.D. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York. Dr. Ernst reports that her spouse has served as a consultant for Neurocrine, Lundbeck, Otsuka, Sunovion, and WebMD; that he is on the speakers’ bureau for Allergan, Neurocrine, Otsuka, Sunovion, Takeda- Lundbeck; and that he receives royalties from American Psychiatric Publishing, Inc. Dr. Ernst reports no financial relationships with commercial interests for herself. The other authors report no financial relationships with commercial interests.
Working With a Patient With Bipolar I Disorder Who Is Experiencing Depression
Jeffrey J. Rakofsky, M.D. Emory University School of Medicine, Atlanta. Dr. Rakofsky reports grant support from Takeda Pharmaceutical Company, the National Institute of Mental Health, and the American Board of Psychiatry and Neurology.
Ethical Issues in the Diagnosis and Treatment of Bipolar Disorders
Michael J. Ostacher, M.D., M.P.H. Department of Psychiatry, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, and Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Palo Alto. Send correspondence to Dr. Ostacher (email@example.com). In the past 36 months, Dr. Ostacher has been a consultant to Alkermes, Johnson & Johnson (Janssen), Lundbeck, Otsuka, Sage Therapeutics, and Supernus Pharmaceuticals; he has received research funding from Palo Alto Health Sciences, Inc.
Xanadu and Mood Stabilization
Ian A. Cook, M.D. Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, and Los Angeles TMS Institute. Dr. Cook reports that the University of California, Los Angeles (UCLA), received research grant funding from NeoSync, Inc., for his work there prior to retirement and that his active biomedical device patents are assigned to the University of California. He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently is on leave as its chief medical officer and senior vice president. Dr. Cook has equity positions and leadership roles in HeartCloud, Inc., and the BrainCloud Corporation.
American Psychiatric Association Staff Involved in Planning:
Tristan Gorrindo, MD Director, Division of Education, APA – no conflicts
Kristen Moeller, Director of CME, Associate Director of FOCUS – no conflicts